We tested the efficacy of three different KRAS inhibitors with divergent modes of action in vitro and in vivo using a battery of 30 natural and transduced human and murine cancer cell lines and four different methods to integrally assess tumor cell growth. The gene discussed is KRAS; the disease is cancer.